Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.72 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.72 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.62 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.53 |
| ▸ | FABP3 | P05413 | 4/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10445389 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL304735 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL10445611 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL14518383 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL10445388 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL23534068 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL16798931 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL304737 | 0.98 | LPAR3 (0.75) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL20139178 | 0.96 | LPAR3 (0.72) | LPAR3LPAR2LPAR1GGPS1S1PR2 | |
| SCHEMBL28090287 | 0.96 | LPAR3 (0.72) | LPAR3LPAR2LPAR1GGPS1S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080063714-A1 | Compositions for Encapsulation and Controlled Release | 3M INNOVATIVE PROPERTIES COMPANY | 2008-03-13 | — | — | US | disclosed |
| EP-1651035-A2 | COMPOSITIONS FOR ENCAPSULATION AND CONTROLLED RELEASE | 3M Innovative Properties Company (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012488-A2 | COMPOSITIONS FOR ENCAPSULATION AND CONTROLLED RELEASE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063714-A1 | Compositions for Encapsulation and Controlled Release | CHMP4B, DDC, ANXA5 | LPAR3 3862/4885LPAR2 4380/4885LPAR1 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.